Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy ; volume:8 ; number:1 ; day:11 ; month:12 ; year:2023 ; pages:1-2 ; date:12.2023
Signal transduction and targeted therapy ; 8, Heft 1 (11.12.2023), 1-2, 12.2023
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-023-01696-x
- URN
-
urn:nbn:de:101:1-2024022307543601405785
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brichkina, Anna
- Suezov, Roman
- Huber, Magdalena
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Minimal change disease associated with anti-PD1 immunotherapy: a case report
PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation
Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Minimal change disease associated with anti-PD1 immunotherapy: a case report
PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation
Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Minimal change disease associated with anti-PD1 immunotherapy: a case report
PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation
Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase
The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target